Role of LXR and ABCA1 in the pathogenesis of Alzheimer's disease - Implications for a new therapeutic approach

Current Alzheimer Research

Volumn 4, Issue 2, 2007, Pages 171-178

  Koldamova, Radosveta ^a   Lefterov, Iliya ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

amyloid; ABCA1; Alzheimer's disease; Apo E; APP transgenic mice; Cholesterol; Liver X receptors; LXR ligands

Indexed keywords

ABC TRANSPORTER A1; AMYLOID BETA PROTEIN; HORMONE RECEPTOR STIMULATING AGENT; LIVER X RECEPTOR; LIVER X RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; GENE TARGETING; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BRAIN; CHOLESTEROL; DNA-BINDING PROTEINS; HUMANS; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 34147176022     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720507780362227     Document Type: Review

References (75)

1. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57: 1439-1443 (2000).
2. Sparks DL, Scheff SW, Hunsaker JC, III, Liu H, Landers T, Gross DR. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 126: 88-94 (1994).
3. Sparks DL, Petanceska S, Sabbagh M, Connor D, Soares H, Adler C, et al. Cholesterol, copper and Abeta in controls, MCI, AD and the AD cholesterol-lowering treatment trial (ADCLT). Curr Alzheimer Res 2: 527-539 (2005).
4. Kalaany NY, Mangelsdorf DJ. LXRs and FXR: The Yin and Yang of Cholesterol and Fat Metabolism. Annu Rev Physiol (2005).
5. Beaven SW, Tontonoz P. Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia. Annu Rev Med 57: 313-329 (2006).
6. Tontonoz P, Mangelsdorf DJ. Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol 17: 985-993 (2003).
7. Oram JF, Heinecke JW. ATP-Binding Cassette Transporter A1: A Cell Cholesterol Exporter That Protects Against Cardiovascular Disease. Physiol Rev 85: 1343-1372 (2005).
8. Hirsch-Reinshagen V, Maia LF, Burgess BL, Blain JF, Naus KE, McIsaac SA, et al. The Absence of ABCA1 Decreases Soluble ApoE Levels but Does Not Diminish Amyloid Deposition in Two Murine Models of Alzheimer Disease. J Bio Chem 280: 43243-43256 (2005).
9. Koldamova R, Staufenbiel M, Lefterov I. Lack of ABCA1 Considerably Decreases Brain ApoE Level and Increases Amyloid Deposition in APP23 Mice. J Biol Chem 280: 43224-43235 (2005).
10. Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, et al. Deletion of Abca1 Increases A{beta} Deposition in the PDAPP Transgenic Mouse Model of Alzheimer Disease. J Biol Chem 280 43236-43242 (2005).
11. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 322 1447-1451 (2001).
12. Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kareholt I, Winblad B, et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 62 1556-1560 (2005).
13. Pappolla MA, Bryant-Thomas TK, Herbert D, Pacheco J, Fabra GM, Manjon M, et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 61 199-205 (2003).
14. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261 921-923 (1993).
15. Humphries SE, Morgan L. Genetic risk factors for stroke and carotid atherosclerosis: insights into pathophysiology from candidate gene approaches. The Lancet Neurology 3: 227-235 (2004).
16. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA, Statins and the risk of dementia. Lancet 356; 1627-1631 (2000).
17. Zlokovic BV. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 28: 202-208 (2005).
18. Refolo LM, Pappolla MA, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 7: 321-331 (2000).
19. Shie FS, Jin LW, Cook DG, Leverenz JB, LeBoeuf RC, Diet-induced hypercholesterolemia enhances brain Abeta accumulation in transgenic mice. Neuroreport 13: 455-459 (2002).
20. Hutter-Paier B, Huttunen HJ, Puglielli L, Eckman CB, Kim DY, Hofmeister A, et al. The ACAT Inhibitor CP-113,818 Markedly Reduces Amyloid Pathology in a Mouse Model of Alzheimer's Disease. Neuron 44: 227-238 (2004).
21. Li L, Cao D, Garber DW, Kim H, Fukuchi K. Association of aortic atherosclerosis with cerebral beta-amyloidosis and learning deficits in a mouse model of Alzheimer's disease. Am J Pathol 163: 2155-2164 (2003).
22. Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, Thomas-Bryant T. et al. A cholesterol-lowering drug reduces betaamyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 8: 890-899 (2001).
23. Winkler DT, Bondolfi L, Herzig MC, Jann L, Calhoun ME, Wiederhold KH, et al. Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy. J Neurosci 21: 1619-1627 (2001).
24. Lutjohann D, Brzezinka A, Barth E, Abramowski D, Staufenbiel M, von Bergmann K, et al. Profile of cholesterol-related sterols in aged amyloid precursor protein transgenic mouse brain. J Lipid Res 43: 1078-1085 (2002).
25. Willy PJ, Umesono K, Ong ES, Evans RM, Heyman RA, Mangelsdorf DJ. LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev 9: 1033 (1995).
26. Claudel T, Leibowitz MD, Fievet C, Tailleux A, Wagner B, Repa JJ. et al. Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc Natl Acad Sci USA 98: 2610-2615 (2001).
27. Repa JJ, Turley SD, Lobaccaro JA, Medina J, Li L, Lustig K, et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 289: 1524-1529 (2000).
28. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, et al. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 7: 161-171 (2001).
29. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nature Med 7: 53-58 (2001).
30. Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nature Genet 22: 352-355 (1999).
31. Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, Diederich W, et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nature Genet 22: 347-351 (1999).
32. Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam M, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nature Genet 22: 336-345 (1999).
33. Hobbs, HH and Rader DJ. ABC1: connecting yellow tonsils, neuropathy, and very low HDL J Clin Invest 104: 1015-1017 (1999).
34. van Dam MJ, de Groot E, Clee SM, Hovingh GK, Roelants R, Brooks-Wilson A, et al. Association between increased arterial wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study. Lancet 359: 37-42 (2002).
35. Wahrle SE, Jiang H, Parsadanian M, Legleiter J, Han X, Fryer JD, et al. ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J Biol Chem 279: 40987-40993 (2004).
36. Yu L, Hammer RE, Li-Hawkins J, Von BK, Lutjohann D, Cohen JC, et al. Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion. Proc Natl Acad Sci USA 99; 16237-16242 (2002).
37. Sun Y, Yao J, Kim TW, Tall AR, Expression of Liver X Receptor Target Genes Decreases Cellular Amyloid {beta} Peptide Secretion. J Biol Chem 278: 27688-27694 (2003).
38. Zelcer N, Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 116: 607-614 (2006).
39. Adighibe O, Arepalli S, Hardy J, Wavrant-De Vrieze F. The Liver X receptor: Candidate gene for Alzheimer's disease. Neurobiol Aging 25: 515 (2005).
40. Wollmer MA, Streffer JR, Lutjohann D, Tsolaki M, Iakovidou V, Hegi T, et al. ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer's disease. Neurobiol Aging 24: 421-426 (2003).
41. Katzov H, Chalmers K, Palmgren J, Andreasen N, Johansson B, Cairns NJ, et al. Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to beta-amyloid metabolism. Hum Mutat 23: 358-367 (2004).
42. Sundar PD, Feingold E, Minster RL, DeKosky ST, Kamboh MI. Gender-specific association of ATP-binding cassette transporter 1 (ABCA1) polymorphisms with the risk of late-onset Alzheimer's disease. Neurobiol Aging (2006).
43. Li Y, Tacey K, Doil L, Luchene Rv, Garcia V, Rowland C, et al. Association of ABCA1 with late-onset Alzheimer's disease is not observed in a case-control study. Neuroscience Lett 366: 268-271 (2004).
44. Shibata N, Kawarai T, Lee JH, Lee HS, Shibata E, Sato C, et al. Association studies of cholesterol metabolism genes (CH25H, ABCA1 and CH24H) in Alzheimer's disease. Neuroscience Lett In Press; (2005).
45. Papassotiropoulos A, Lutjohann D, Bagli M, Locatelli S, Jessen F, Buschfort R, et al. 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J Psychiatr Res 36: 27-32 (2002).
46. Kolsch H, Lutjohann D, Ludwig M, Schulte A, Ptok U, Jessen F, et al., Polymorphism in the cholesterol 24S-hydroxylase gene is associated with Alzheimer's disease. Mol Psychiatry 7: 899-902 (2002).
47. Papassotiropoulos A, Wollmer MA, Tsolaki M, Brunner F, Molyva D, Lutjohann D, et al. A cluster of cholesterol-related genes confers susceptibility for Alzheimer's disease. J Clin Psychiatry 66 940-947 (2005).
48. Dietschy JM, Turley SD, Cholesterol metabolism in the brain. Curr Opin Lipidol 12: 105-112 (2001).
49. Lund EG, Guileyardo JM, Russell DW, cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc Natl Acad Sci USA 96: 7238-7243 (1999).
50. Lund EG, Xie C, Kotti T, Turley SD, Dietschy JM, Russell DW. Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. J Biol Chem 278: 22980-22988 (2003).
51. Nakai M, Kawamata T, Taniguchi T, Maeda K, Tanaka C. Expression of apolipoprotein E mRNA in rat microglia. Neurosci Lett 211: 41-44 (1996).
52. Poirier J, Baccichet A, Dea D, Gauthier S, Cholesterol synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult rats. Neuroscience 55: 81-90 (1993).
53. Weiler-Guttler, H, Sommerfeldt M, Papandrikopoulou A, Mischek U, Bonitz D, Frey A, et al. Synthesis of apolipoprotein A-1 in pig brain microvascular endothelial cells. J Neurochem 54: 444-450 (1990).
54. Koldamova RP, Lefterov IM, Ikonomovic MD, Skoko J, Lefterov PI, Isanski BA, et al. 22R-Hydroxycholesterol and 9-cis-retinoic acid induce ABCA1 transporter expression and cholesterol efflux in brain cells and decrease Aβ secretion. J Biol Chem 278: 13244-13256 (2003).
55. Wellington CL, Walker EK, Suarez A, Kwok A, Bissada N, Singaraja R, et al. ABCA1 mRNA and Protein Distribution Patterns Predict Multiple Different Roles and Levels of Regulation. Lab Invest 82: 273-283 (2002).
56. Whitney KD, Watson MA, Collins JL, Benson WG, Stone TM, Numerick MJ, et al. Regulation of cholesterol homeostasis by the liver x receptors in the central nervous system. Mol Endocrinol 16: 1378-1385 (2002).
57. Hirsch-Reinshagen V, Zhou S, Burgess BL, Bernier L, McIsaac SA, Chan JY, et al. Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. J Biol Chem 279: 41197-41207 (2004).
58. Simons K, Ikonen E. Functional rafts in cell membranes. Nature 387: 569-572 (1997).
59. Kalvodova L, Kahya N, Schwille P, Ehehalt R, Verkade P, Drechsel D, et al. Lipids as modulators of proteolytic activity of BACE: involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro. J Biol Chem 280: 36815-36823 (2005).
60. Ehehalt R, Keller P, Haass C, Thiele C, Simons K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol 160: 113-123 (2003).
61. Vetrivel KS, Cheng H, Lin W, Sakurai T, Li T, Nukina N, et al. Association of {gamma}-Secretase with Lipid Rafts in Post-Golgi and Endosome Membranes. J Biol Chem 279: 44945-44954 (2004).
62. Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F. From the Cover: Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10. Proc Natl Acad Sci USA 98: 5815-5820 (2001).
63. Prinzen C, Muller U, Endres K, Fahrenholz F, Postina R, Genomic structure and functional characterization of the human ADAM10 promoter. FASEB J 04-3619fje (2005).
64. Molander-Melin M, Blennow K, Bogdanovic N, Dellheden B, Mansson JE, Fredman P. Structural membrane alterations in Alzheimer brains found to be associated with regional disease development; increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent-resistant membrane domains. J Neurochem 92: 171-182 (2005).
65. Brown J, III, Theisler C, Silberman S, Magnuson D, Gottardi-Littell N, Lee JM, et al. Differential Expression of Cholesterol Hydroxylases in Alzheimer's Disease. J Biol Chem 279: 34674-34681 (2004).
66. Fukumoto H, Deng A, Irizarry MC, Fitzgerald ML, Rebeck GW, Induction of the Cholesterol Transporter ABCA1 in Central Nervous System Cells by Liver X Receptor Agonists Increases Secreted Abeta Levels. J Biol Chem 277: 48508-48513 (2002).
67. Burns MP, Vardanian L, Pajoohesh-Ganji A, Wang L, Cooper M, Harris DC, et al. The effects of ABCA1 on cholesterol efflux and Abeta levels in vitro and in vivo. J Neurochem 98; 792-800 (2006).
68. Koldamova RP, Lefterov IM, Staufenbiel M, Wolfe D, Huang S, Glorioso JC, et al. The Liver X Receptor Ligand T0901317 Decreases Amyloid {beta} Production in Vitro and in a Mouse Model of Alzheimer's Disease. J Biol Chem 280: 4079-4088 (2005).
69. Riddell DR, Zhou H, Kirsley Y, Atchinson K, Aschmies S, Comery T, et al. The role of liver X receptor (LXR) agonists in modulating A?? levels in vitro and in vivo, Alzheiemer's and Dementia. The J Alzhe Asso 2: S539 (2006).
70. Rigamonti E, Helin L, Lestavel S, Mutka AL, Lepore M, Fontaine C, et al. Liver X receptor activation controls intracellular cholesterol trafficking and esterification in human macrophages. Circ Res 97: 682-689 (2005).
71. Puglielli L, Konopka G, Pack-Chung E, Ingano LA, Berezovska O, Hyman BT, et al. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat Cell Biol 3: 905-912 (2001).
72. Sun Y, Hao M, Luo Y, Liang Cp, Silver DL, Cheng C, et al. Stearoyl-CoA Desaturase Inhibits ATP-binding Cassette Transporter A1-mediated Cholesterol Efflux and Modulates Membrane Domain Structure. J Biol Chem 278; 5813-5820 (2003).
73. Liang Y, Lin S, Beyer TP, Zhang Y, Wu X, Bales KR, et al. A liver X receptor and retinoid X receptor heterodimer mediates apolipo protein E expression, secretion and cholesterol homeostasis in astrocytes. J Neurochemistry 88: 623-634 (2004).
74. Lefterov I, Koldamova R, Staufenbiel M, Ikonomovic MD, Isanski BA, DeKosky ST, et al. LXR ligand treatment in vitro and in vivo is followed by ABCA1 upregulation and decrease in A-beta secretion. Neurobiol Aging 25: S569 (2004).
75. Wahrle S, Jiang H, Parsadanian M, Holtzman DM. An LXR agonist increases brain ApoE in wild type but no ABCA1-/- mice. Society for Neuroscience Conference, Washington, D.C. Soc Neurosci Abstr 35:81.9: 2005.